|Issuer:||ELEDON PHARMACEUTICALS, INC. (ELDN)|
|Original Submission Date:|
SMITH BRYAN E.
C/O ELEDON PHARMACEUTICALS, INC.
19900 MACARTHUR BLVD., SUITE 550 IRVINE, CA 92612
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|STOCK OPTION (RIGHT TO BUY)||9.91||2021-05-03||deemed execution date||A||158,500 (a)||2031-05-03||common stock 158,500||$9.91||158,500||direct|
|f1||this option represents a right to purchase up to 158,500 shares of common stock, which option vests with respect to 39,625 shares on may 3, 2022, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending may 3, 2025.|